797-63-7|Levonorgestrel |MuseChem

Levonorgestrel


CAS No. : 797-63-7

Levonorgestrel ,797-63-7
Product Details
Cat No:A000355
Synonyms:Norgestrel; 797-63-7; D-Norgestrel; Microval; Postinor
Molecular Formula:C21H28O2
Molecular Weight:312.5
Target:Estrogen/progestogen Receptor
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Appearance:Solid powder
Purity: > 98%
Cat No:A000355
Cas No:797-63-7
Product-Name:Levonorgestrel
InChI:1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
InChIKey:WWYNJERNGUHSAO-XUDSTZEESA-N
SMILES:CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34
Levonorgestrel is a manufactured hormone used in a number of birth control methods. In pill form, it is useful within 120 hours as emergency birth control. It becomes less effective the longer after sex and only works before pregnancy has occurred. It is also combined with an estrogen to make combined oral birth control pill. Within an IUD, it is effective for long term prevention of pregnancy. An implantable form of levonorgestrel is also marketed in some countries.
1: Shaaban OM, Abbas AM, Mahmoud HR, Yones EM, Hassen SG, Zakherah MS. Counseling and in-advance provision of levonorgestrel emergency contraceptive pills decrease the rate of unplanned pregnancy during breastfeeding: a randomized controlled trial. J Matern Fetal Neonatal Med. 2017 Nov 8:1-111. doi: 10.1080/14767058.2017.1403580. [Epub ahead of print] PubMed PMID: 29117764.
2: Alegre-Del Rey EJ, Fénix-Caballero S, Díaz-Navarro J. [Controversies about the mechanism of postcoital levonorgestrel: evidences according to the decrease of pregnancies]. Farm Hosp. 2017 Nov 1;41(6):696-697. doi: 10.7399/fh.10811. Spanish. PubMed PMID: 29112497.
3: Cardoso PG, Loganimoce EM, Neuparth T, Rocha MJ, Rocha E, Arenas F. Interactive effects of increased temperature, pCO(2) and the synthetic progestin levonorgestrel on the fitness and breeding of the amphipod Gammarus locusta. Environ Pollut. 2017 Oct 25. pii: S0269-7491(17)32868-3. doi: 10.1016/j.envpol.2017.10.065. [Epub ahead of print] PubMed PMID: 29102173.
4: Bahamondes L, Fernandes A, Bahamondes MV, Juliato CT, Ali M, Monteiro I. Pregnancy outcomes associated with extended use of the 52-mg 20μg/day levonorgestrel-releasing intrauterine system beyond 60months: A chart review of 776 women in Brazil. Contraception. 2017 Oct 18. pii: S0010-7824(17)30495-X. doi: 10.1016/j.contraception.2017.10.007. [Epub ahead of print] PubMed PMID: 29055780.
5: Yao G, Quan G, Lin S, Peng T, Wang Q, Ran H, Chen H, Zhang Q, Wang L, Pan X, Wu C. Novel dissolving microneedles for enhanced transdermal delivery of levonorgestrel: In vitro and in vivo characterization. Int J Pharm. 2017 Oct 16;534(1-2):378-386. doi: 10.1016/j.ijpharm.2017.10.035. [Epub ahead of print] PubMed PMID: 29051119.
6: Nappi RE, Lobo Abascal P, Hsieh J, Micheletti MC. Cycle control with an extended-regimen oral contraceptive combining levonorgestrel and ethinyl estradiol that includes continuous low-dose ethinyl estradiol instead of the traditional hormone-free interval. Int J Womens Health. 2017 Oct 5;9:739-747. doi: 10.2147/IJWH.S142078. eCollection 2017. PubMed PMID: 29042818; PubMed Central PMCID: PMC5633331.
7: Darney PD, Stuart GS, Thomas MA, Cwiak C, Olariu A, Creinin MD. Amenorrhea rates and predictors during 1 year of levonorgestrel 52 mg intrauterine system use. Contraception. 2017 Oct 13. pii: S0010-7824(17)30482-1. doi: 10.1016/j.contraception.2017.10.005. [Epub ahead of print] PubMed PMID: 29038072.
8: Pandey S. Re: Immediate versus delayed initiation of the levonorgestrel-releasing intrauterine system following medical termination of pregnancy - 1-year continuation rates: a randomised controlled trial: Levonorgestrel-releasing intrauterine system following medical termination of pregnancy: a randomised controlled trial. BJOG. 2017 Oct 5. doi: 10.1111/1471-0528.14901. [Epub ahead of print] PubMed PMID: 28980385.
9: Amiri M, Nahidi F, Khalili D, Bidhendi-Yarandi R, Ramezani Tehrani F. Comparing the Effects of Oral Contraceptives Containing Levonorgestrel With Products Containing Antiandrogenic Progestins on Clinical, Hormonal, and Metabolic Parameters and Quality of Life in Women With Polycystic Ovary Syndrome: Crossover Randomized Controlled Trial Protocol. JMIR Res Protoc. 2017 Sep 29;6(9):e191. doi: 10.2196/resprot.8631. PubMed PMID: 28963092; PubMed Central PMCID: PMC5640820.
10: Ashraf MN, Habib-Ur-Rehman A, Shehzad Z, AlSharari SD, Murtaza G. Clinical efficacy of levonorgestrel and norethisterone for the treatment of chronic abnormal uterine bleeding. J Pak Med Assoc. 2017 Sep;67(9):1331-1338. PubMed PMID: 28924270.
Related Products
  • CAS No. :881639-98-1
    Product Name:

    G-1

    Cat No: I010784 View details
  • CAS No. :190791-29-8
    Product Name:

    Lasofoxifene tartrate

    Cat No: I002447 View details
  • CAS No. :53846-50-7
    Product Name:

    8-Prenylnaringenin

    Cat No: R064414 View details
  • CAS No. :524684-52-4
    Product Name:

    Prinaberel

    Cat No: I003918 View details